Retatrutide and trizepatide constitute a recent class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor https://estelleloio325640.widblog.com/93485101/novel-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide